RxDoctor Payments DataLook up a doctor →

Manohar Ahuja, MD

Nephrology · Milwaukee, WINPI 1467426064

Payments from drug & device makers

$34,555in general payments, 2019–2025

Across 509 payments — averaging $67.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$17K
  • Boehringer Ingelheim$5K
  • AstraZeneca$2K
  • Astrazeneca UK Limited$2K
  • Amgen$2K
  • Travere Therapeutics, Inc.$1K
  • plus $6K from 36 others

What the payments were for

  • Speaking & faculty fees$19,57057%
  • Travel & lodging$3,1779%
  • Food & beverage$11,58734%
  • Education$2221%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,555 in reported general payments places this provider in the 90th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$160,685
Medicare patients
204
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol152$104,148
JardianceEmpagliflozin142$103,605
VelphoroSucroferric Oxyhydroxide27$80,124
XphozahTenapanor Hcl18$78,659
RayaldeeCalcifediol40$60,665
KerendiaFinerenone40$28,805
ClinolipidFat Emulsion/Olive/Soy/Phospho74$26,001
LokelmaSodium Zirconium Cyclosilicate25$13,819
ProsolParenteral Amino Acid 20% No.196$13,391
Sevelamer Carbonate55$6,316
Bumetanide111$2,557
Calcium Acetate57$2,135
Allopurinol244$1,919
Furosemide193$1,641
Febuxostat13$1,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,992$117,967177 claims
Boehringer IngelheimJardiance$4,587$103,605142 claims
Fresenius USA Marketing, Inc.Velphoro$180$80,12427 claims
OPKO Pharmaceuticals, LLCRayaldee$264$60,66540 claims
BayerKerendia$422$28,80540 claims
ANI Pharmaceuticals, Inc.Valsartan$638$62721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →